Results 211 to 220 of about 63,989 (248)
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
New England Journal of Medicine, 2010 Rupert M Bauersachs +2 more
exaly +2 more sources
Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve
New England Journal of Medicine, 2020 BACKGROUND The effects of rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve remain uncertain. METHODS In this randomized trial, we compared rivaroxaban (20 mg once daily) with dose-adjusted warfarin (target international
Renato D Lopes +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Safety and Efficacy of Rivaroxaban in Primary Total Hip and Knee Arthroplasty.
Journal of Arthroplasty, 2023INTRODUCTION An optimal venous thromboembolism (VTE) prophylaxis agent should balance efficacy and safety. While rivaroxaban provides effective VTE prophylaxis after total joint arthroplasty, it may be associated with higher rates of bleeding. This study
Amit S. Piple +7 more
semanticscholar +1 more source
Rivaroxaban versus Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial.
Chest, 2021BACKGROUND Direct oral anticoagulants (DOACs) are an alternative to low-molecular-weight heparin for treating cancer-associated venous thromboembolism (VTE).
B. Planquette +24 more
semanticscholar +1 more source
Drugs of Today, 2007
There is a real and viable need in the anticoagulant arena for a safe, robust, effective oral anticoagulant drug that measures up to warfarin in providing protection against thrombosis and compares favorably (if not better) with regard to safety profile, without the need for routine and often cumbersome monitoring.
Puneet, Kakar +2 more
openaire +2 more sources
There is a real and viable need in the anticoagulant arena for a safe, robust, effective oral anticoagulant drug that measures up to warfarin in providing protection against thrombosis and compares favorably (if not better) with regard to safety profile, without the need for routine and often cumbersome monitoring.
Puneet, Kakar +2 more
openaire +2 more sources
Annals of Internal Medicine, 2022
BACKGROUND Current guidelines recommend using direct oral anticoagulants (DOACs) over warfarin in patients with atrial fibrillation (AF), but head-to-head trial data do not exist to guide the choice of DOAC.
W. Lau +12 more
semanticscholar +1 more source
BACKGROUND Current guidelines recommend using direct oral anticoagulants (DOACs) over warfarin in patients with atrial fibrillation (AF), but head-to-head trial data do not exist to guide the choice of DOAC.
W. Lau +12 more
semanticscholar +1 more source
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
New England Journal of Medicine, 2012 Harry R Büller +2 more
exaly +2 more sources
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation.
New England Journal of MedicineBACKGROUND Abelacimab is a fully human monoclonal antibody that binds to the inactive form of factor XI and blocks its activation. The safety of abelacimab as compared with a direct oral anticoagulant in patients with atrial fibrillation is unknown ...
Christian T. Ruff +18 more
semanticscholar +1 more source
Italian Registry in the Setting of Atrial Fibrillation Ablation with Rivaroxaban - IRIS.
Minerva cardiology and angiologyBACKGROUND Catheter ablation (CA) of atrial fibrillation is routinely used to obtain rhythm control. Evidence suggest that catheter ablation should be done during uninterrupted oral anticoagulation.
Carlo Lavalle +15 more
semanticscholar +1 more source